Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Approves Soliris for Generalized Myasthenia Gravis

By Joanne Van Zuidam | October 27, 2017

The U.S. Food and Drug Administration (FDA) has approved eculizumab (Soliris) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive.

Approval was granted to Alexion Pharmaceuticals, Inc. and was based on results from their phase 3, placebo-controlled REGAIN study.

Myasthenia gravis (MG) is a progressive autoimmune disease that begins with weakness in the muscles that control the eyes and eyelids and often progresses to a more severe form, generalized myasthenia gravis (gMG), which affects the head, neck, trunk, limb, and respiratory muscles.

Current treatments effectively control the symptoms of MG, however, those options do not work for about 10 to 15 percent of patients with anti-AchR antibody-positive gMG.

That subset of patients suffer from significant unresolved disease symptoms, such as difficulties seeing, walking, talking, swallowing, and breathing. Exacerbations of these symptoms may require hospitalization and intensive care and may be life-threatening.

A disabling neuromuscular disorder

In patients with anti-AchR antibody-positive gMG, the body’s own immune system turns on itself to produce antibodies against AchR, a receptor located on muscle cells at the neuromuscular junction (NMJ) and used by nerve cells to communicate with the muscles these nerves control.

The binding of these antibodies to AchR activates the complement cascade, another part of the immune system, which leads to a localized inflammation and destruction of the muscle membrane at the NMJ.  As a result, the communication between nerve and muscle is impaired, which in turn leads to a loss of normal muscle function.   

According to the company, Soliris works by selectively inhibiting the terminal complement cascade, targeting a critical underlying cause of the disease.

“It is exciting that patients who have not responded adequately to existing therapies will now have a new treatment option that was shown in clinical studies to improve patients’ symptoms, their ability to carry out activities of daily living and their quality of life,” said Professor James F. Howard, M.D., Department of Neurology at the University of North Carolina, Chapel Hill, and lead investigator in the clinical development of this new indication, in a statement.

Also commenting in the statement, Nancy Law, chief executive officer of the Myasthenia Gravis Foundation of America (MGFA) said: “This is a landmark day for the members of the U.S. myasthenia gravis community, who have not seen a therapy approved for generalized myasthenia gravis in more than 60 years.”  

Soliris is already approved in the European Union (EU) for the treatment of refractory gMG in adults who are anti-AchR antibody-positive as well as for patients with the ultra-rare disorders paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

The treatment is one of the most expensive therapies worldwide, costing more than $500,000 per year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE